



**FOR IMMEDIATE RELEASE**

Contact: Dr. Dan Stinchcomb, 970-231-2290

**InViragen Meets Funding Milestone and Opens Facility**

Fort Collins, CO. May 17, 2006

InViragen, LLC, a biotechnology company dedicated to developing vaccines for emerging market opportunities worldwide, has successfully raised over \$1 million in funding. The funds, derived from both grants and individual investors, will be used to initiate InViragen's vaccine research and development activities. With the receipt of these funds, InViragen has opened an office and laboratory facility in Fort Collins, Colorado.

In December 2005, InViragen was awarded a grant from the Regional Center for Excellence in Biodefense and Emerging Disease that may provide over \$210,000 to support West Nile vaccine research. In March 2006, InViragen received a Small Business Biodefense grant of over \$660,000 from the National Institutes of Allergy and Infectious Disease, to support its plague and smallpox vaccine research. Recently, InViragen completed an initial closing on a seed round of financing, receiving \$130,000 from individual investors.

"The receipt of two significant, peer-reviewed grants validates our vaccine technologies," said Dr. Dan Stinchcomb, InViragen's Chief Executive Officer. "We also are pleased to have received investor support; these early investors are committed to InViragen's mission of developing new vaccines to improve global public health."

InViragen has leased a facility in Fort Collins, Colorado, has recently completed the needed tenant improvements to convert the space to functional office

and laboratory space, and has hired key members of its scientific staff. “We are excited to see one of the newest Incubator clients meet these financial and operational goals,” said Kathy Kregel, Executive Director of the Fort Collins Technology Incubator. “InViragen is already contributing to economic growth and the growth of biotechnology in Northern Colorado.”

XXX

### **About InViragen**

Over 15 million people worldwide die each year of infectious diseases. Vaccines to prevent these diseases are the most cost effective solutions to improving global health. Co-founded by Dr. Jorge Osorio and Dr. Dan Stinchcomb, InViragen is committed to developing vaccines to address this need. InViragen’s lead vaccine is intended to protect against dengue fever. Dengue is a disease that potentially affects 2.5 billion people in tropical regions throughout the world as well as millions of travelers to those countries. InViragen is developing a vaccine to protect against West Nile disease. West Nile spread throughout the United States and North America since its introduction in the Western Hemisphere in 1999. InViragen is also designing a vaccine to protect against plague and smallpox, both of which are dangerous bioterrorist threats. InViragen has offices in Fort Collins, Colorado and Madison, Wisconsin.

### **About the Fort Collins Technology Incubator**

The City of Fort Collins, Colorado State University, Colorado State University Research Foundation and the Northern Colorado EDC fund the Fort Collins Technology Incubator which focuses its resources on technology based startups in the Fort Collins region.